The COVID-19 pandemic exacerbated a national mental-health crisis in the United States. Drug overdose deaths have climbed rapidly over the past 20 years, and suicide rates have gradually increased. Psilocybin and other psychedelics have shown great promise in treating mental health conditions, but their use is severely limited by legal and social obstacles.
Over the past decade, medical and scientific communities have increasingly recognized the potential of psychedelic therapies for the treatment of intractable mental health conditions. Legal and logistical barriers to innovation have remained as the range of potential uses for psychedelic substances has expanded. Accessing a reliable,